In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells

Fusion oncogenes (FO) are common in cancers, but specific targeting of these chimeric genes are challenging. Here the authors report a CRISPR/Cas9 strategy that targets two intronic regions to disrupt the FOs in cancer cells and show that this approach reduces tumour growth and prolongs survival in...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	M. Martinez-Lage, R. Torres-Ruiz, P. Puig-Serra, P. Moreno-Gaona, M. C. Martin, F. J. Moya, O. Quintana-Bustamante, S. Garcia-Silva, A. M. Carcaboso, P. Petazzi, C. Bueno, J. Mora, H. Peinado, J. C. Segovia, P. Menendez, S. Rodriguez-Perales
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/734f530d0a9c4f49995b0d8094e4f389
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:734f530d0a9c4f49995b0d8094e4f389
record_format	dspace
spelling	oai:doaj.org-article:734f530d0a9c4f49995b0d8094e4f3892021-12-02T17:13:19ZIn vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells10.1038/s41467-020-18875-x2041-1723https://doaj.org/article/734f530d0a9c4f49995b0d8094e4f3892020-10-01T00:00:00Zhttps://doi.org/10.1038/s41467-020-18875-xhttps://doaj.org/toc/2041-1723Fusion oncogenes (FO) are common in cancers, but specific targeting of these chimeric genes are challenging. Here the authors report a CRISPR/Cas9 strategy that targets two intronic regions to disrupt the FOs in cancer cells and show that this approach reduces tumour growth and prolongs survival in animal models of cancer.M. Martinez-LageR. Torres-RuizP. Puig-SerraP. Moreno-GaonaM. C. MartinF. J. MoyaO. Quintana-BustamanteS. Garcia-SilvaA. M. CarcabosoP. PetazziC. BuenoJ. MoraH. PeinadoJ. C. SegoviaP. MenendezS. Rodriguez-PeralesNature PortfolioarticleScienceQENNature Communications, Vol 11, Iss 1, Pp 1-14 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q M. Martinez-Lage R. Torres-Ruiz P. Puig-Serra P. Moreno-Gaona M. C. Martin F. J. Moya O. Quintana-Bustamante S. Garcia-Silva A. M. Carcaboso P. Petazzi C. Bueno J. Mora H. Peinado J. C. Segovia P. Menendez S. Rodriguez-Perales In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells
description	Fusion oncogenes (FO) are common in cancers, but specific targeting of these chimeric genes are challenging. Here the authors report a CRISPR/Cas9 strategy that targets two intronic regions to disrupt the FOs in cancer cells and show that this approach reduces tumour growth and prolongs survival in animal models of cancer.
format	article
author	M. Martinez-Lage R. Torres-Ruiz P. Puig-Serra P. Moreno-Gaona M. C. Martin F. J. Moya O. Quintana-Bustamante S. Garcia-Silva A. M. Carcaboso P. Petazzi C. Bueno J. Mora H. Peinado J. C. Segovia P. Menendez S. Rodriguez-Perales
author_facet	M. Martinez-Lage R. Torres-Ruiz P. Puig-Serra P. Moreno-Gaona M. C. Martin F. J. Moya O. Quintana-Bustamante S. Garcia-Silva A. M. Carcaboso P. Petazzi C. Bueno J. Mora H. Peinado J. C. Segovia P. Menendez S. Rodriguez-Perales
author_sort	M. Martinez-Lage
title	In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells
title_short	In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells
title_full	In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells
title_fullStr	In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells
title_full_unstemmed	In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells
title_sort	in vivo crispr/cas9 targeting of fusion oncogenes for selective elimination of cancer cells
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/734f530d0a9c4f49995b0d8094e4f389
work_keys_str_mv	AT mmartinezlage invivocrisprcas9targetingoffusiononcogenesforselectiveeliminationofcancercells AT rtorresruiz invivocrisprcas9targetingoffusiononcogenesforselectiveeliminationofcancercells AT ppuigserra invivocrisprcas9targetingoffusiononcogenesforselectiveeliminationofcancercells AT pmorenogaona invivocrisprcas9targetingoffusiononcogenesforselectiveeliminationofcancercells AT mcmartin invivocrisprcas9targetingoffusiononcogenesforselectiveeliminationofcancercells AT fjmoya invivocrisprcas9targetingoffusiononcogenesforselectiveeliminationofcancercells AT oquintanabustamante invivocrisprcas9targetingoffusiononcogenesforselectiveeliminationofcancercells AT sgarciasilva invivocrisprcas9targetingoffusiononcogenesforselectiveeliminationofcancercells AT amcarcaboso invivocrisprcas9targetingoffusiononcogenesforselectiveeliminationofcancercells AT ppetazzi invivocrisprcas9targetingoffusiononcogenesforselectiveeliminationofcancercells AT cbueno invivocrisprcas9targetingoffusiononcogenesforselectiveeliminationofcancercells AT jmora invivocrisprcas9targetingoffusiononcogenesforselectiveeliminationofcancercells AT hpeinado invivocrisprcas9targetingoffusiononcogenesforselectiveeliminationofcancercells AT jcsegovia invivocrisprcas9targetingoffusiononcogenesforselectiveeliminationofcancercells AT pmenendez invivocrisprcas9targetingoffusiononcogenesforselectiveeliminationofcancercells AT srodriguezperales invivocrisprcas9targetingoffusiononcogenesforselectiveeliminationofcancercells
_version_	1718381324699435008

In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells

Ejemplares similares